Treatment and Demographic Factors Affecting Time to Next Pulmonary Exacerbation in Cystic Fibrosis

Overview

Journal J Cyst Fibros

Publisher Elsevier

Specialty Pulmonary Medicine

Date 2015 Mar 11

PMID 25754096

Citations 21

Authors

Donald R VanDevanter

David J Pasta

Michael W Konstan

Affiliations

Soon will be listed here.

Abstract

Background: Pulmonary exacerbations (PEx) are important CF clinical events.

Methods: We studied time to next PEx following intravenous (IV) antibiotic PEx treatment among Cleveland Ohio CF center patients occurring between January 2010 and September 2014. Patient demographics, clinical presentations, and treatments were modeled by Cox proportional hazards regression to identify covariates associated with time to next PEx.

Results: 193 patients were treated for PEx; 155 had a subsequent IV-treated PEx. Six covariates were associated with future PEx hazard: number of PEx in the prior year (hazard ratio 25.1 for ≥3 and 4.4 for 1-2 prior-year PEx versus none; P<.0001), IV treatment duration in weeks (1.2; P=.0004), percent hospital treatment (1.1; P=.0018), and chronic inhaled aminoglycosides (2.5; P<.0001), leukotriene modifiers (1.8; P=.0031), and high dose ibuprofen (0.52; P=.0006).

Conclusions: Time to next PEx was profoundly associated with prior-year PEx, suggestive of high-risk PEx phenotypes that warrant recognition and further study.

Citing Articles

Vitamin D deficiency in patients with cystic fibrosis: a systematic review and meta-analysis.

Farahbakhsh N, Fatahi S, Shirvani A, Motaharifard M, Mohkam M, Tabatabaii S J Health Popul Nutr. 2024; 43(1):11.

PMID: 38233891 PMC: 10795301. DOI: 10.1186/s41043-024-00499-2.

Pulmonary exacerbations in early cystic fibrosis lung disease are marked by strong modulation of CD3 and PD-1 on luminal T cells.

Giacalone V, Giraldo D, Silva G, Hosten J, Peng L, Guglani L Front Immunol. 2023; 14:1194253.

PMID: 37809107 PMC: 10551126. DOI: 10.3389/fimmu.2023.1194253.

Diagnosis and Management of Cystic Fibrosis Exacerbations.

Milinic T, McElvaney O, Goss C Semin Respir Crit Care Med. 2023; 44(2):225-241.

PMID: 36746183 PMC: 10131792. DOI: 10.1055/s-0042-1760250.

Role of inhaled antibiotics in the era of highly effective CFTR modulators.

Elborn J, Blasi F, Burgel P, Peckham D Eur Respir Rev. 2023; 32(167).

PMID: 36631132 PMC: 9879329. DOI: 10.1183/16000617.0154-2022.

Autogenic drainage for airway clearance in cystic fibrosis.

Burnham P, Stanford G, Stewart R Cochrane Database Syst Rev. 2021; 12:CD009595.

PMID: 34910295 PMC: 8672941. DOI: 10.1002/14651858.CD009595.pub3.

References

Goss C, Burns J . Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax. 2007; 62(4):360-7. PMC: 2092469. DOI: 10.1136/thx.2006.060889. View

Murphy T, Anbar R, Lester L, Nasr S, Nickerson B, VanDevanter D . Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol. 2004; 38(4):314-20. DOI: 10.1002/ppul.20097. View

Konstan M, Morgan W, Butler S, Pasta D, Craib M, Silva S . Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr. 2007; 151(2):134-9, 139.e1. DOI: 10.1016/j.jpeds.2007.03.006. View

Sequeiros I, Jarad N . Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis. Chron Respir Dis. 2012; 9(1):9-16. DOI: 10.1177/1479972311433575. View

Ferkol T, Rosenfeld M, Milla C . Cystic fibrosis pulmonary exacerbations. J Pediatr. 2006; 148(2):259-64. DOI: 10.1016/j.jpeds.2005.10.019. View

Britto M, Kotagal U, Hornung R, Atherton H, Tsevat J, Wilmott R . Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest. 2002; 121(1):64-72. DOI: 10.1378/chest.121.1.64. View

Hankinson J, Odencrantz J, Fedan K . Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999; 159(1):179-87. DOI: 10.1164/ajrccm.159.1.9712108. View

Smith A, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M . Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr. 1999; 134(4):413-21. DOI: 10.1016/s0022-3476(99)70197-6. View

De Boer K, Vandemheen K, Tullis E, Doucette S, Fergusson D, Freitag A . Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax. 2011; 66(8):680-5. DOI: 10.1136/thx.2011.161117. View

10.

Konstan M, Byard P, Hoppel C, DAVIS P . Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995; 332(13):848-54. DOI: 10.1056/NEJM199503303321303. View

11.

Waters V, Stanojevic S, Atenafu E, Lu A, Yau Y, Tullis E . Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J. 2011; 40(1):61-6. DOI: 10.1183/09031936.00159111. View

12.

Sanders D, Li Z, Brody A . Chest computed tomography predicts the frequency of pulmonary exacerbations in children with cystic fibrosis. Ann Am Thorac Soc. 2014; 12(1):64-9. PMC: 5466157. DOI: 10.1513/AnnalsATS.201407-338OC. View

13.

Ramsey B, Pepe M, Quan J, Otto K, Montgomery A, Borowitz D . Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999; 340(1):23-30. DOI: 10.1056/NEJM199901073400104. View

14.

Amadori A, Antonelli A, Balteri I, Schreiber A, Bugiani M, De Rose V . Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis. Respir Med. 2008; 103(3):407-13. DOI: 10.1016/j.rmed.2008.09.024. View

15.

Wang X, Dockery D, Wypij D, Fay M, FERRIS Jr B . Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol. 1993; 15(2):75-88. DOI: 10.1002/ppul.1950150204. View

16.

VanDevanter D, Yegin A, Morgan W, Millar S, Pasta D, Konstan M . Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint. J Cyst Fibros. 2011; 10(6):453-9. PMC: 4079110. DOI: 10.1016/j.jcf.2011.07.003. View

17.

Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss C, Aitken M . Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med. 2002; 166(12 Pt 1):1550-5. DOI: 10.1164/rccm.200202-087OC. View

18.

Lieu T, Ray G, Farmer G, Shay G . The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics. 1999; 103(6):e72. DOI: 10.1542/peds.103.6.e72. View

19.

Liou T, Adler F, FitzSimmons S, Cahill B, Hibbs J, Marshall B . Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001; 153(4):345-52. PMC: 2198936. DOI: 10.1093/aje/153.4.345. View

20.

VanDevanter D, Konstan M . Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease. Clin Investig (Lond). 2015; 2(2):163-175. PMC: 4486293. DOI: 10.4155/cli.11.174. View